Prognosis after heart transplant in patients with hypertrophic and restrictive cardiomyopathy. A nationwide registry analysis

Posttransplant outcomes among recipients with a diagnosis of hypertrophic cardiomyopathy (HCM) or restrictive cardiomyopathy (RCM) remain controversial. Retrospective analysis of a nationwide registry of first-time recipients undergoing isolated heart transplant between 1984 and 2021. One-year and 5...

Full description

Saved in:
Bibliographic Details
Published in:Revista española de cardiología (English ed.) 2024-04, Vol.77 (4), p.304-313
Main Authors: González-Urbistondo, Francisco, Almenar-Bonet, Luis, Gómez-Bueno, Manuel, Crespo-Leiro, Marisa, González-Vílchez, Francisco, García-Cosío, María Dolores, López-Granados, Amador, Mirabet, Sonia, Martínez-Sellés, Manuel, Sobrino, José Manuel, Díez-López, Carles, Farrero, Marta, Díaz-Molina, Beatriz, Rábago, Gregorio, de la Fuente-Galán, Luis, Garrido-Bravo, Iris, Blasco-Peiró, María Teresa, García-Quintana, Antonio, Vázquez de Prada, José Antonio
Format: Article
Language:eng ; spa
Subjects:
Cardiomyopathy restrictive
Cardiomyopathy, Dilated - surgery
Cardiomyopathy, Hypertrophic - diagnosis
Cardiomyopathy, Hypertrophic - surgery
Cardiomyopathy, Restrictive - surgery
Heart Transplantation
Humans
Hypertrophic cardiomyopathy
Miocardiopatía hipertrófica
Miocardiopatía restrictiva
Prognosis
Pronóstico
Registries
Retrospective Studies
Trasplante de corazón
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Posttransplant outcomes among recipients with a diagnosis of hypertrophic cardiomyopathy (HCM) or restrictive cardiomyopathy (RCM) remain controversial. Retrospective analysis of a nationwide registry of first-time recipients undergoing isolated heart transplant between 1984 and 2021. One-year and 5-year mortality in recipients with HCM and RCM were compared with those with dilated cardiomyopathy (DCM). We included 3703 patients (3112 DCM; 331 HCM; 260 RCM) with a median follow-up of 5.0 [3.1-5.0] years. Compared with DCM, the adjusted 1-year mortality risk was: HCM: HR, 1.38; 95%CI, 1.07-1.78; P=.01, RCM: HR, 1.48; 95%CI, 1.14-1.93; P=.003. The adjusted 5-year mortality risk was: HCM: HR, 1.17; 95%CI, 0.93-1.47; P=.18; RCM: HR, 1.52; 95%CI, 1.22-1.89; P
ISSN:1885-5857
1885-5857
DOI:10.1016/j.rec.2023.10.006